Altamira Therapeutics

Historical price data

Altamira Therapeutics operates a dual-track strategy, balancing a commercial-stage consumer health asset with earlier-stage, platform-based therapeutic development. Its core innovation is the xPhore™ platform, a peptide nanoparticle system designed to solve the critical challenge of delivering RNA therapeutics to tissues beyond the liver. The company's mission is to address unmet medical needs in allergy, viral infections, and inner ear disorders, leveraging a partnership-driven out-licensing model for its platform while building a pipeline of proprietary CNS candidates. This structure is intended to mitigate risk and create multiple value inflection points.

xPhore™ is a peptide-based nanoparticle platform engineered for the efficient delivery of various nucleic acid payloads (siRNA, mRNA, circRNA, DNA) to extrahepatic tissues, addressing a key bottleneck in RNA therapeutics.

Faces intense competition in RNA delivery from well-funded LNP and novel modality companies. Bentrio® competes in a niche segment against other barrier sprays and large OTC pharmaceutical marketers. CNS/inner ear therapeutic development is a high-risk field with several peers having faced clinical failures.